Analysis of interferon-beta therapy and certain miRNA levels in people with multiple sclerosis

Takeaway

  • MicroRNA miR-185-5p may serve as a novel biomarker for monitoring the response to interferon-beta (IFN-β) therapy in individuals with relapse-remitting multiple sclerosis (RRMS).

Why this matters

    The mechanism of IFN-β for treating individuals with RRMS remains unknown.

Want to read more?

Log in or sign up to access all Neurodiem content.

Already have an account? Log In

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.